The U.S. Food and Drug Administration (FDA) has approved Celltrion’s AVTOZMA (CT-P47, tocilizumab-anoh) in both an ...
The FDA approved Avtozma, a tocilizumab biosimilar developed by Celltrion, for the treatment of several rheumatic conditions.
JERSEY CITY, NJ, USA I January 30, 2025 I Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved AVTOZMA® (CT-P47, ...
The intravenous biosimilar of IL-6 inhibitor Actemra (tocilizumab) – called Tofidence (formerly BIIB800) – has been cleared for three of the indications for which Roche’s drug is used ...
Medpage Today on MSN3mon
Old Drugs, New Tricks: The Power of Medication RepurposingIn the end, it was the lesser-known repurposed drugs that received far less attention that ended up saving the most lives: ...
The European Commission has approved the first biosimilar version of Actemra/RoActemra ... offering of both intravenous and subcutaneous formulations of tocilizumab and is targeting the number ...
Monoclonal antibodies are novel therapeutic agents used with great success in the treatment of rheumatoid arthritis ... that interfere with IL-6 function Tocilizumab is a monoclonal antibody ...
The company aims to secure its "first mover" position through the approval of Korea's first Actemra biosimilar while also stepping up its efforts to penetrate the global tocilizumab market.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback